

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Previously Presented) A method for inhibiting endothelial cell adhesion, endothelial cell migration and/or angiogenesis, comprising administering to a subject in need thereof an effective amount of:

an isolated peptide comprising an amino acid sequence represented by (I, D, E or K)-(E, A or Q)-L-(L, R or A)-(N, D or S)-(A, L, K or I)-(L or Y)-(R, N, L or K)-(Y or N)-H-(M, I or G)-(V, L, Q or G)-(G, K, T or D)-(R, S, L or E)-(R, A, E or I)-(V, M, T or L)-(L, C or V)-(T, A, G or S).

2-3. (Canceled).

4. (Previously Presented). The method of Claim 1, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 23 to SEQ ID NO: 26.

5. (Previously Presented) The method of Claim 1, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17 to SEQ ID NO: 22.

6. (Previously Presented) The method of Claim 5, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 16.

7. (Currently Amended) A method for the treatment of an angiogenesis-related disease, comprising administering to a subject in need thereof an effective amount of:

an isolated peptide comprising an amino acid sequence represented by (I, D, E or K)-(E, A or Q)-L-(L, R or A)-(N, D or S)-(A, L, K or I)-(L or Y)-(R, N, L or K)-(Y or N)-H-

(M, I or G)-(V, L, Q or G)-(G, K, T or D)-(R, S, L or E)-(R, A, E or I)-(V, M, T or L)-(L, C or V)-(T, A, G or S), wherein:

the angiogenesis-related disease is selected from the group consisting of: cancer; ~~vascular malformation, arteriosclerosis, vascular adhesions, edematous sclerosis, corneal graft neovascularization, neovascular glaucoma, diabetic retinopathy, pterygium, retinal degeneration, retrolental fibroplasia, granular conjunctivitis, and~~ rheumatoid arthritis; systemic Lupus erythematosus, thyroiditis, psoriasis, pyogenic granuloma, seborrheic dermatitis and acne.

8-12. (Canceled).

13. (Previously Presented). The method of Claim 7, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 23 to SEQ ID NO: 26.

14. (Previously Presented) The method of Claim 7, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17 to SEQ ID NO: 22.

15. (Previously Presented) The method of Claim 7, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11 to SEQ ID NO: 16.

16. (New) The method of claim 7, wherein the angiogenesis-related disease is cancer.

17. (New) The method of claim 7, wherein the angiogenesis-related disease is rheumatoid arthritis.